Amgen drops ph. 1 obesity drug, upping pressure on MariTide
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Amgen drops ph. 1 obesity drug, upping pressure on MariTide" is generating significant coverage in the Business category, with 10 articles from 10 distinct sources tracked by PULSE so far.
Outlets currently covering the story include qz.com, PR Newswire, Breakingthenews.net and FirstWord PHARMA. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 89d ago.
Quick answers
Why is "Amgen drops ph. 1 obesity drug, upping pressure on MariTide" trending?
Because 10 independent news sources published 10 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513 qz.com · 91d ago
- AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS PR Newswire · 91d ago
- Amgen Q2 revenue tops projections at $10.1B, up 10% Breakingthenews.net · 91d ago
- Amgen remains bullish on Repatha, axes obesity asset in 2Q report FirstWord PHARMA · 91d ago
- Amgen (AMGN) To Report Earnings Tomorrow: Here Is What To Expect Yahoo Finance · 91d ago
- Amgen Lifts Outlook After Blockbuster Sales Top Expectations bloomberg.com · 91d ago
- Amgen Boosts Sales View By $1 Billion After Smashing Views Investor's Business Daily · 91d ago
- Amgen rides Repatha renaissance as cardio wins keep cholesterol med's momentum rolling Fierce Pharma · 91d ago
- Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment WSJ · 91d ago
- Amgen drops ph. 1 obesity drug, upping pressure on MariTide Fierce Biotech · 91d ago
Topics
Related trends
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
Amgen reports that combining Imdelltra with Imfinzi reduces the risk of death by 58% for patients with first-line extensive stage small cell lung cancer.
How to prevent osteoporosis, from training to eating calcium-rich food
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
Amgen announces positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease.
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Novartis experiences a trial failure with pelacarsen, impacting the Dow and raising questions for competitors like Amgen and Lilly.
Stock Market Today: Dow tumbles 1%, S&P 500 and Nasdaq drop as Brent crude edges toward $100 a barrel and pharma stocks stumble
U.S. stocks tumble as crude oil approaches $100 per barrel and inflation data approaches.
Cholesterol drug setback casts doubt over multibillion-dollar race
A failed Novartis clinical trial for a cholesterol drug has triggered a biopharma selloff and cast doubt on competing efforts by Amgen and Eli Lilly.